156 related articles for article (PubMed ID: 32856050)
21. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
Dubray CL; Sircar AD; Beau de Rochars VM; Bogus J; Direny AN; Ernest JR; Fayette CR; Goss CW; Hast M; O'Brian K; Pavilus GE; Sabin DF; Wiegand RE; Weil GJ; Lemoine JF
PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008298. PubMed ID: 32511226
[TBL] [Abstract][Full Text] [Related]
23. The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea.
Weil GJ; Kastens W; Susapu M; Laney SJ; Williams SA; King CL; Kazura JW; Bockarie MJ
PLoS Negl Trop Dis; 2008; 2(12):e344. PubMed ID: 19065257
[TBL] [Abstract][Full Text] [Related]
24. Effect of annual mass administration of diethylcarbamazine and albendazole on bancroftian filariasis in five villages in south India.
Ramaiah KD; Vanamail P; Yuvaraj J; Das PK
Trans R Soc Trop Med Hyg; 2011 Aug; 105(8):431-7. PubMed ID: 21601901
[TBL] [Abstract][Full Text] [Related]
25. Persistence of lymphatic filarial infection in the paediatric population of rural community, after six rounds of annual mass drug administrations.
Sunish IP; Munirathinam A; Kalimuthu M; Ashok Kumar V; Tyagi BK
J Trop Pediatr; 2014 Jun; 60(3):245-8. PubMed ID: 24343822
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic Filariasis Prevalence in Flores Island, Indonesia.
Supali T; Djuardi Y; Lomiga A; Nur Linda S; Iskandar E; Goss CW; Miller JP; Weil GJ; Fischer PU
Am J Trop Med Hyg; 2019 Feb; 100(2):336-343. PubMed ID: 30560772
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae.
Supali T; Ismid IS; Rückert P; Fischer P
Trop Med Int Health; 2002 Oct; 7(10):894-901. PubMed ID: 12358626
[TBL] [Abstract][Full Text] [Related]
28. Reassessment of areas with persistent Lymphatic Filariasis nine years after cessation of mass drug administration in Sri Lanka.
Rao RU; Samarasekera SD; Nagodavithana KC; Dassanayaka TDM; Punchihewa MW; Ranasinghe USB; Weil GJ
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006066. PubMed ID: 29084213
[TBL] [Abstract][Full Text] [Related]
29. Endpoints for lymphatic filariasis programs.
Grady CA; de Rochars MB; Direny AN; Orelus JN; Wendt J; Radday J; Mathieu E; Roberts JM; Streit TG; Addiss DG; Lammie PJ
Emerg Infect Dis; 2007 Apr; 13(4):608-10. PubMed ID: 17553278
[TBL] [Abstract][Full Text] [Related]
30. The effect of repeated half-yearly diethylcarbamazine mass treatment on Wuchereria bancrofti infection and transmission in two East African communities with different levels of endemicity.
Simonsen PE; Meyrowitsch DW; Mukoko DA; Pedersen EM; Malecela-Lazaro MN; Rwegoshora RT; Ouma JH; Masese N; Jaoko WG; Michael E
Am J Trop Med Hyg; 2004 Jan; 70(1):63-71. PubMed ID: 14971700
[TBL] [Abstract][Full Text] [Related]
31. Changes in Wuchereria bancrofti infection in a highly endemic community following 10 rounds of mass administration of diethylcarbamazine.
Ramaiah KD; Vanamail P; Das PK
Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):250-5. PubMed ID: 16890256
[TBL] [Abstract][Full Text] [Related]
32. Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial.
Hoti SL; Pani SP; Vanamail P; Athisaya Mary K; Das LK; Das PK
Natl Med J India; 2010; 23(2):72-6. PubMed ID: 20925201
[TBL] [Abstract][Full Text] [Related]
33. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Thomsen EK; Sanuku N; Baea M; Satofan S; Maki E; Lombore B; Schmidt MS; Siba PM; Weil GJ; Kazura JW; Fleckenstein LL; King CL
Clin Infect Dis; 2016 Feb; 62(3):334-341. PubMed ID: 26486704
[TBL] [Abstract][Full Text] [Related]
34. The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.
de Rochars MB; Kanjilal S; Direny AN; Radday J; Lafontant JG; Mathieu E; Rheingans RD; Haddix AC; Streit TG; Beach MJ; Addiss DG; Lammie PJ
Am J Trop Med Hyg; 2005 Nov; 73(5):888-94. PubMed ID: 16282299
[TBL] [Abstract][Full Text] [Related]
35. Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets.
Jones C; Ngasalla B; Derua YA; Tarimo D; Malecela MN
Int J Infect Dis; 2017 Aug; 61():38-43. PubMed ID: 28527817
[TBL] [Abstract][Full Text] [Related]
36. Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment.
Kar SK; Dwibedi B; Das BK; Agrawala BK; Ramachandran CP; Horton J
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0005631. PubMed ID: 29059186
[TBL] [Abstract][Full Text] [Related]
37. Imported bancroftian filariasis: diethylcarbamazine response and benzimidazole susceptibility of Wuchereria bancrofti in dynamic cross-border migrant population targeted by the National Program to Eliminate Lymphatic Filariasis in South Thailand.
Bhumiratana A; Pechgit P; Koyadun S; Siriaut C; Yongyuth P
Acta Trop; 2010 Feb; 113(2):121-8. PubMed ID: 19835831
[TBL] [Abstract][Full Text] [Related]
38. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.
Kroidl I; Saathof E; Maganga L; Clowes P; Maboko L; Hoerauf A; Makunde WH; Haule A; Mviombo P; Pitter B; Mgeni N; Mabuye J; Kowuor D; Mwingira U; Malecela MN; Löscher T; Hoelscher M
PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004618. PubMed ID: 27070786
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous response of Wuchereria bancrofti-infected persons to diethylcarbamazine (DEC) and its implications for the Global Programme to Eliminate Lymphatic Filariasis (GPELF).
Sankari T; Subramanian S; Hoti SL; Pani SP; Jambulingam P; Das PK
Parasitol Res; 2021 Jan; 120(1):311-319. PubMed ID: 33146778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
